Amgen announces global diagnostic collaborations
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510. AMG 510 is the first KRASG12C inhibitor to advance to the clinic for
Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen's preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim's leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company's extensive range of therapeutic antibodies targeting this pathway.
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery
- Details
- Category: Bayer
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities.
Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, to Catalent Inc.
Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
- Details
- Category: AstraZeneca
AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D).
Amgen commences strategic collaboration with BeiGene to expand oncology presence in China
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market. BeiGene is a commercial-stage research-based oncology company with an established and highly experienced team in China,
Lilly opens Phase 3 clinical trial in RET-mutant medullary thyroid cancer
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naive RET-mutant medullary thyroid cancer (MTC) patients. This is the second Phase 3 trial to open for selpercatinib, a highly selective and potent, oral investigational new medicine in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase.
More Pharma News ...
- Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
- Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program
- Amgen and Allergan submit Biologics License Application for ABP 798, biosimilar candidate to Rituxan® (rituximab)
- Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
- Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
- Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
- New set-up for IT at Bayer